Thallion attempts to tame Jaguar ahead of Bellus acquisition vote
This article was originally published in Scrip
Executive Summary
Canadian firm Thallion Pharmaceuticals will hold a shareholder meeting on 6 August to vote on the proposed acquisition of Thallion by Bellus Health. Thallion's board is keen for the deal to proceed, but its largest single shareholder, Jaguar Financial which holds 10.1%, has indicated it will vote against the deal unless terms are increased.